Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Basten, J. P.
Right arrow Articles by Schraffordt Koops, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Basten, J. P.
Right arrow Articles by Schraffordt Koops, H.

Annals of Surgical Oncology, Vol 4, Issue 4 342-348, Copyright © 1997 by Society of Surgical Oncology

ARTICLES

Cisplatin-based chemotherapy changes the incidence of bilateral testicular cancer

J. P. van Basten, H. J. Hoekstra, M. F. van Driel, D. T. Sleijfer, J. H. Droste and H. Schraffordt Koops
Department of Surgical Oncology, University Hospital, Groningen, The Netherlands.

BACKGROUND: The introduction of cisplatin-based chemotherapy has remarkably increased the survival of testicular cancer patients. With this success, the concern for a contralateral testicular tumor has increased. The aim of this study was to investigate whether the risk for contralateral testicular tumor development was influenced by cisplatin-based chemotherapy. METHODS: The incidence of a contralateral testicular tumor among 365 consecutive patients with a nonseminoma testicular tumor, diagnosed in the period 1980 and 1995, was established and related to previous therapy. RESULTS: Eleven of 365 men (3%) developed a contralateral testicular tumor. After a total of 2403 person-years at risk, 4 of 225 chemotherapy-treated patients (1.8%) developed a contralateral testicular tumor, and 7 of 140 patients (5%) treated with orchidectomy alone developed a contralateral tumor. In comparison to this surveillance subgroup, patients previously treated with chemotherapy have a relative risk of 0.30 to develop a second testicular tumor. CONCLUSIONS: In Dutch men with a nonseminoma testicular tumor, the incidence of a contralateral testicular tumor is 3%, which is 60-fold the expected incidence rate of testicular cancer. A three times lower incidence rate of a contralateral testicular tumor was found in the chemotherapy subgroup compared with those on surveillance. This supports the hypothesis that cisplatin-based chemotherapy may eradicate carcinoma in situ or early testicular cancer.


This article has been cited by other articles:


Home page
 Hum ReprodHome page
F-M. Kohn, I. Schroeder-Printzen, W. Weidner, M. Montag, H. van der Ven, and W-B. Schill
Testicular sperm extraction in a patient with metachronous bilateral testicular cancer: Case report
Hum. Reprod., November 1, 2001; 16(11): 2343 - 2346.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the Society of Surgical Oncology.